

### Biliary Tract Cancers

<p><b>ECOG-ACRIN EA2187</b> <b>NCT04175912</b> Temp suspended 3/31/21</p>	<p>A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma</p>
---	---

### BioBanking

<p><b>Notable Labs N-01</b></p>	<p>An Observational Study to Collect and Assess Tissue Samples From Subjects With Documented Hematologic Malignancy (ANSWer) - Cohorts currently open are AML, MDS and MPN</p>
---------------------------------	--

### Brain

<p><b>NRG BN007</b> <b>NCT04396860</b> DTL required</p>	<p>A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab vs. Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma</p>
---	--

### Breast - Neoadjuvant

<p><b>Alliance A011202</b> <b>NCT01901094</b></p>	<p>A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy</p>

### Breast - DCIS

<p><b>AFT-25 COMET</b> <b>NCT02926911</b></p>	<p>Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial</p>
---	--

## Breast - Adjuvant Triple Negative

<b>Alliance A211601</b> <b>NCT03609021</b>	Evaluation of Mammographic Breast Density Effect of Aspirin: A companion study to Alliance Study A011502
<b>NRG-BR003</b> <b>NCT02488967</b>	A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Invasive Breast Cancer

## BREAST - Adjuvant HR Positive

### BREAST - Adjuvant HER2+

<b>ECOG-ACRIN EA1181</b> <b>NCT04266249</b>	(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
--	---

## Breast - Adjuvant XRT

<b>CCTG MA.39</b> <b>NCT03488693</b>	A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
<b>SWOG S1706</b> <b>NCT03598257</b>	A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy alone for Inflammatory Breast Cancer

## Breast - Metastatic

<b>NRG BR004</b> <b>NCT03199885</b> <b>DTL Required - Temp</b> <b>Closed to Accrual</b> <b>6/23/2021</b>	A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
--	--

## Breast - Locally Advanced/Metastatic HER2+/HR+

## ER+/HER2-

<b>DFCI 17-101 PACE</b> <b>NCT03147287</b>	Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-Treated ER+/HER2- Metastatic Breast Cancer
---	--

## Triple Negative

## Longitudinal Study

<b>DFCI 18-634 ELEVATE</b> <b>NCT03818087</b>	ELEVATE: Improving Outcomes for Older Patients with Breast Cancer: A Longitudinal Cohort and Patient Engagement Study
--	---

## Radiation

<b>DFCI 16-304</b> <b>NCT03422003</b>	Study of Radiation Fractionation on Patient Outcomes After Breast Reconstruction (FABREC) for Invasive Breast Carcinoma
--	---

## Children's Oncology Group Registry

<b>APEC14B1 (Patient's 25 and Younger)</b>	Project EveryChild: A Registry, Eligibility Screening, Biology and Outcome Registry
--	---

## Colorectal

<b>Alliance A021502</b> <b>NCT02912559</b> <b>DTL Required</b>	Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
<b>Alliance A021703</b> <b>NCT04094688</b>	Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
<b>NRG GI004</b> <b>NCT02997228</b> <b>DTL Required</b>	NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

## Colorectal

<b>NRG-GI005</b> <b>NCT04068103</b>	Phase II/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
<b>SWOG S1820</b> <b>NCT04205955</b>	A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
<b>SWOG S1922</b> <b>NCT04205968</b>	Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

## COVID-19

<b>NCI COVID-19</b> <b>NCT04387656</b>	NCI COVID-19 in Cancer Patients study(N-CCaPS): A Longitudinal Natural History Study
---	--

## Gastroesophageal

<b>EA2174</b> <b>NCT03604991</b>	A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
-------------------------------------	---

## Genitourinary

<b>Alliance A031501</b> <b>NCT03244384</b>	Phase III randomized "Adjuvant study of MK-3475 (pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma" (AMBASSADOR) versus observation
<b>ECOG EA8185</b> <b>NCT04216290</b>	Phase II Study of Bladder-Sparing Chemoradiation With MEDI4736 (durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)

## GYN

<b>NRG GY009</b> <b>NCT02839707</b>	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
<b>NRG GY014</b> <b>NCT03348631</b> Temp. closed to accrual	A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
<b>NRG GY019</b> <b>NCT04095364</b>	A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin /Maintenance Letrozole vs Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
<b>DFCI 20-065</b> <b>NCT04354454</b>	Step into Support for Endurance and Strength

## Hodgkin Lymphoma

<b>S1826</b> <b>NCT03907488</b>	A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vendotin(Adcetris) Plus AVD in Patients (Ag3 >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
------------------------------------	---

## Leukemia - Untreated/Newly Diagnosed

<b>Alliance A041701</b> <b>NCT03701308</b> DTL Required	A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
<b>Alliance A041702</b> <b>NCT03737981</b>	A Randomized Phase III Trial of Ibrutinib Plus Obintuzumab versus Ibrutinib Plus Venetoclax and Obintuzumab in Untreated Older Patients ( $\geq 70$ ) Years of Age) with Chronic Lymphocytic Leukemia (CLL)
<b>DFCI 18-089</b> <b>NCT03534323</b>	A Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Patients or Patients with Richter's Syndrome
<b>DFCI 18-226</b> <b>NCT03580928</b>	A Phase 2 Study of Acalabrutinib, Venetoclax, and Obintuzumab (AVO) for Initial Therapy of Chronic Lymphocytic Leukemia

## Lung Cancer - Screening Adjuvant

<b>Alliance A151216 (ALCHEMIST) NCT02194738</b>	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
---	--

## Lung Cancer - Adjuvant

<b>Alliance A081801 NCT04267848</b>	Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
<b>ECOG E4512 (ALCHEMIST) NCT 02201992</b>	A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
<b>SWOG 1827 NCT04155034</b>	MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
<b>SWOG 1900E NCT04625647</b>	Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

## Lung Cancer - Unresectable

<b>ECOG-ACRIN EA5181 NCT04092283</b>	Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
--	---

## Lung Cancer - 1st Line Metastatic

<b>ECOG-ACRIN EA5163 NCT03793179</b>	INSIGNIA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Non-squamous, Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis
--	--

## Lung Cancer - 2nd Line Metastatic

<b>LUNGMAP NCT02154490</b>	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
--------------------------------	--

## Lymphoma

<b>Alliance A051701 NCT03984448</b>	Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MC/BCL2 Double-Hit and Double-Expressing Lymphomas
<b>ECOG-ACRIN EA4181 NCT04115631</b>	A Randomized 3 Arm Phase II Study Comparing 1) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR), 2) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients $\leq$ 70 Years old with Untreated Mantle Cell Lymphoma

## Melanoma - Locally Advanced Metastatic

<b>ECOG-ACRIN EA6141 NCT02339571</b>	Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
--	--

## Melanoma - Adjuvant

<b>SWOG S1801 NCT03698019</b>	A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
-----------------------------------	---

## Merkel Cell

<b>EA6174 NCT03712605</b>	STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, A Phase III Trial
-------------------------------	--

## Multiple Tumor Types

<b>ECOG-ACRIN EAY131 (MATCH) NCT02465060</b>	Molecular Analysis for Therapy Choice (MATCH)
--	---

## Myeloma

<b>SWOG S1803 NCT04071457</b>	Phase III Study of Daratumumab/HuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as PostAutologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)
<b>AFT-41 NCT04009109</b>	A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma

## Myeloma - Relapsed/Refractory

### Prevention

<b>Alliance A151804</b> <b>NCT04242095</b>	Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
<b>Alliance A221805</b> <b>NCT04137107</b>	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

### Prostate

<b>AFT-19</b> <b>NCT03009981</b>	A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
<b>SWOG S1802</b> <b>NCT03678025</b>	Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
<b>NRG-GU008</b> <b>NCT04134260</b> <b>Temp. Closed to</b> <b>Accrual</b>	Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy

### Rare Tumors

<b>SWOG S1609</b> <b>NCT02834013</b>	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
<b>TAPUR</b> <b>NCT02693535</b>	The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

### Renal

<b>Alliance A031704</b> <b>(PDIGREE)</b> <b>NCT03793166</b>	PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGFTKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)
---	--